Schroder Investment Management Group
RLMD icon

Schroder Investment Management Group’s Relmada Therapeutics RLMD Stock Holding History

Schroder Investment Management Group’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,000
Closed -$41.4K – 1237
2023
Q4 		$41.4K Buy
+10,000
New +$29.6K ﹤0.01% 1175

Other funds holding RLMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Schroder Investment Management Group's RLMD Position: Q1 2024 in Review

Schroder Investment Management Group sold out of Relmada Therapeutics (RLMD) in Q1 2024, closing a stake of 10,000 shares — an estimated $41.4K sold.

Schroder Investment Management Group first reported a position in RLMD in Q4 2023 and held it in 1 quarter. The position peaked at $41.4K in Q4 2023. 93 funds tracked by Wall St. Rank hold RLMD as of Q1 2024.

  • Schroder Investment Management Group reported no remaining Relmada Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Schroder Investment Management Group sold 10,000 Relmada Therapeutics shares in Q1 2024, an estimated $41.4K.
  • Schroder Investment Management Group first reported a position in Relmada Therapeutics in Q4 2023 and held it in 1 quarter.
  • Schroder Investment Management Group's Relmada Therapeutics position peaked at $41.4K in Q4 2023.
  • 93 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2024.

Based on Schroder Investment Management Group's 13F filing for Q1 2024, filed 14 May 2024.